Evidence map›Paper›PMID 39512644›Full record

ReviewRSC advances2024

Advances in quinoxaline derivatives: synthetic routes and antiviral efficacy against respiratory pathogens.

Fateme Dehnavi, Malihe Akhavan, Ahmadreza Bekhradnia

Abstract readReview
In one paragraph

Review in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. NovelMolecules (Basel, Switzerland) · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fateme DehnaviPharmaceutical Sciences Research Center, Department of Medicinal Chemistry, Mazandaran University of Medical Sciences Sari Iran abekhradnia@gmail.com abekhradnia@mazums.ac.ir.
Malihe AkhavanPharmaceutical Sciences Research Center, Department of Medicinal Chemistry, Mazandaran University of Medical Sciences Sari Iran abekhradnia@gmail.com abekhradnia@mazums.ac.ir.ORCID https://orcid.org/0000-0001-6041-6989
Ahmadreza BekhradniaPharmaceutical Sciences Research Center, Department of Medicinal Chemistry, Mazandaran University of Medical Sciences Sari Iran abekhradnia@gmail.com abekhradnia@mazums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study of quinoxalines as nitrogen-rich heterocyclic compounds has garnered substantial interest within scientific research owing to their multidimensional functionalization capabilities and significant biological activities. The scope of study encompasses their application as potent antiviral agents, particularly within the domain of respiratory pathologies-a topic of pivotal concern in this comprehensive review. They have several prominent pharmacological effects, such as potential influenza inhibitors, potential anti-SARS coronavirus inhibitors, potential anti-SARS-CO-2 coronavirus inhibitors, and miscellaneous respiratory antiviral activities. As a result, some of the literature has described many of these quinoxalines using various synthetic methods for their mentioned biological effects. In the present review, we provided insight into quinoxaline synthesis, structure-activity relationship (SAR), and antiviral activities, along with a compilation of recent studies. The article further encapsulates the gamut of past and ongoing research efforts in the design and synthetic exploration of antiviral scaffolds, with a pronounced emphasis on their strategic deployment against viral pandemics, contextualized against the tapestry of the recent COVID-19 outbreak. This illuminates the quintessential role of quinoxalines in the armamentarium against viral pathogens and provides a platform for the development of next-generation antiviral agents.

Identifiers

PMID39512644
PMCPMC11542553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.